Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Madrigal Pharmaceuticals (Nasdaq: MDGL) announced it will participate in the Canaccord Genuity Annual Growth Conference on Tuesday, August 11, 2026, at 12:00 p.m. EDT.

Rhea-AI Summary

Madrigal Pharmaceuticals (Nasdaq: MDGL) announced it will participate in the Canaccord Genuity Annual Growth Conference on Tuesday, August 11, 2026, at 12:00 p.m. EDT. The company’s presentation will be webcast live, with access via Madrigal’s Investor Relations Events and Presentations page, and a replay available after the event.

Argus Aug 6 session

-0.73% close to close Open Argus

Details

News Market Reaction – MDGL

In the Aug 6 session, MDGL declined 0.73%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

News ID 1077398 was followed by 2.67% after a partnership milestone, providing a relevant comparison...

Analysis

News ID 1077398 was followed by 2.67% after a partnership milestone, providing a relevant comparison for this event-only announcement. The notice contained no results; low short positioning remained a volatility-risk consideration.

Key Figures

Conference edition: 46th Annual Growth Conference Presentation date: Aug. 11, 2026 Presentation time: 12:00 P.M. EDT

Conference edition

46th Annual Growth Conference

Canaccord Genuity conference

Presentation date

Aug. 11, 2026

Scheduled conference presentation

Presentation time

12:00 P.M. EDT

Scheduled conference presentation

Historical Context

5 past events · Latest: Jul 21

5 events

1. Jul 21

   Inducement awards

   24h Move

   -1.7%

   Equity awards granted to ten new non-executive employees under the inducement plan

2. Jul 16

   Earnings scheduling

   24h Move

   -0.9%

   Company scheduled second-quarter financial results and a management webcast

3. Jul 13

   Patent grants

   24h Move

   -1.1%

   USPTO issued three patents covering resmetirom treatment regimens and administration

4. Jul 06

   Inducement awards

   24h Move

   +3.0%

   Equity awards granted to seven new non-executive employees under the inducement plan

5. Jul 01

   Partnership milestone

   24h Move

   +2.7%

   Ribo and Madrigal nominated a MASH candidate and began IND-enabling studies

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46^th Annual Growth Conference on Tuesday, Aug. 11, 2026 at 12:00 P.M. EDT.

The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Madrigal Pharmaceuticals (MDGL) present at the Canaccord Genuity Annual Growth Conference in 2026?

Madrigal Pharmaceuticals will present on Tuesday, August 11, 2026, at 12:00 p.m. EDT. According to Madrigal, this session is part of the Canaccord Genuity Annual Growth Conference and will be available to investors via live webcast.

How can investors access Madrigal Pharmaceuticals’ (MDGL) webcast for the August 11, 2026 Canaccord conference?

Investors can access the live webcast through a provided online link or via Madrigal’s Investor Relations Events and Presentations page. According to Madrigal, the webcast will cover the company’s conference participation and will be available at the scheduled time.

Will a replay be available for Madrigal Pharmaceuticals’ (MDGL) August 11, 2026 conference webcast?

Yes, a replay of Madrigal Pharmaceuticals’ webcast will be available after the event. According to Madrigal, investors who cannot watch live can later access the recorded presentation through the company’s Investor Relations Events and Presentations page.

What is the significance of Madrigal Pharmaceuticals (MDGL) joining the Canaccord Genuity Annual Growth Conference in August 2026?

Madrigal’s participation provides an opportunity to present its story to growth-focused investors. According to Madrigal, the session will be publicly accessible by webcast, allowing broader investor audiences to hear management’s comments and review the replay afterward.

What time zone is used for Madrigal Pharmaceuticals’ (MDGL) August 11, 2026 Canaccord conference presentation time?

The presentation time of 12:00 p.m. is stated in Eastern Daylight Time (EDT). According to Madrigal, this schedule applies to the company’s session at the Canaccord Genuity Annual Growth Conference and guides when the live webcast will begin.